Phibro Animal Health Corporation Reiterates Safety Of Mecadox And Intent To Defend Its Use For Customers
Portfolio Pulse from Benzinga Newsdesk
The FDA has issued a final order to revoke the approved method for detecting residues of carbadox, a drug marketed by Phibro Animal Health Corporation (NASDAQ:PAHC), and proposed to withdraw approval of all new animal drug applications for use of carbadox in medicated swine feed. Phibro has expressed disappointment in the FDA's actions and reiterated its belief in the safety of Mecadox, which has been approved and sold in the US for over 50 years. The company intends to defend its use for customers.
November 07, 2023 | 3:26 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Phibro Animal Health Corporation's drug Mecadox is under scrutiny by the FDA, which could potentially impact the company's revenues and reputation. The company plans to defend the drug's use.
The FDA's actions against Mecadox, a drug marketed by Phibro, could potentially lead to a withdrawal of approval for the drug's use in medicated swine feed. This could negatively impact Phibro's revenues from the sale of Mecadox. However, the company's intent to defend the drug's use could mitigate some of this potential impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100